Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.38

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received a consensus rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.3750.

Separately, Wall Street Zen upgraded shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $3.85 on Friday. Maravai LifeSciences has a twelve month low of $1.95 and a twelve month high of $4.11. The firm has a market cap of $989.72 million, a P/E ratio of -4.28 and a beta of 0.62. The company has a 50 day moving average of $3.30 and a 200 day moving average of $3.39. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The company had revenue of $49.87 million during the quarter, compared to analyst estimates of $49.06 million. As a group, research analysts expect that Maravai LifeSciences will post -0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences

Hedge funds have recently added to or reduced their stakes in the company. Sprott Inc. purchased a new stake in Maravai LifeSciences during the 3rd quarter valued at $29,000. Virtu Financial LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $34,000. Insigneo Advisory Services LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $34,000. Quantessence Capital LLC purchased a new stake in Maravai LifeSciences during the 3rd quarter valued at $31,000. Finally, Stifel Financial Corp purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $36,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.